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Abstract
Background: Aromatase inhibitors prevent the aromatization of androgens into
estrogens, which reduces the negative feedback of estrogen on the hypothalamic-
pituitary axis. It is clear that increasing the secretion of follicle-stimulating hormones
results in an increased follicular growth.
Objective: This study aimed to evaluate the effect of adding letrozole to gonadotropin
on in vitro fertilization outcomes in normal responders.
Materials and Methods: In this randomized clinical trial, 100 normal responder women
candidate for controlled ovarian stimulation were randomly enrolled in two groups (n
= 50/each). In the case group letrozole was added to gonadotropin in the antagonist
protocol. The control group received the conventional antagonist protocol. The main
outcome was clinical and chemical pregnancy; and the second outcomes were the
number of mature oocytes, the fertilization rate, estradiol level, and the total dose of
gonadotropins.
Results: Basic clinical and demographic features were comparable between the
groups. Estradiol level on the day of human-chorionic-gonadotropin administration
and the total gonadotropin consumption were significantly higher in the control group
than the case group (p = 0.045). In addition, the number of MII oocytes was higher
(but not significantl) in the case group than the control group (p = 0.09). Moreover,
the endometrial thickness was significantly lower in the case group. There were no
significant differences in fertilization rate and chemical and clinical pregnancy rates
between the two groups.
Conclusion: Although adding letrozole to gonadotropin in normal responders reduces
the total dose of gonadotropin, it does not improve the pregnancy outcomes.
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1. Introduction
Letrozole is a major aromatase inhibitor that
is used to treat infertility and subfertility. The
aromatase enzyme is blocked by letrozole, which
inhibits the conversion of androgen into estrogen
and the subsequent increase in intraovarian
androgens (1). Existing studies suggest that
androgens play a significant role in developing
ovarian follicles (2, 3). In the process of estrogen
biosynthesis, aromatase plays a rate-limiting role;
suppressing this role reduces estrogen levels as
well as the negative feedback caused by estrogen
on the secretion of gonadotropin (1).
Stimulating the endogenous generation of
gonadotropin by the feedback of negative
mechanisms minimizes the necessity of
exogenous gonadotropin and in vitro fertilization
(IVF) cycle costs (4). Moreover, aromatase
inhibitors do not diminish the estrogen
receptors that exist in the endometrium and
the hypothalamic-pituitary axis. In addition, apart
from stimulating endogenous gonadotropin,
a momentary intrafollicular-androgenic
environment is created by aromatase inhibitors
that could improve the follicular reaction to
follicle-stimulating hormones (FSHs) through
the sensitization and overexpression of FSH
receptors (4-6).
Letrozole has no antiestrogenic impact on
endometrium (7). In addition, in normal women
who undergo in vitro fertilization (IVF), lowering
the levels of follicular and serum estrogen
may help to reduce the possibility of ovarian
hyperstimulation syndrome (OHSS) (8). This is
because a relationship has been established
between the use of letrozole and a reduction
in the OHSS incidence rate (9). Such reports
have motivated us to suppose that the use of
letrozole as a co-therapy factor in the antagonist
gonadotropin-releasing hormone (GnRH) protocol
in normal responders’ cycles improves cycle
outcomes.
Accordingly, this study aimed to compare the
IVF outcomes of normal responders who have
received gonadotropin both with and without the
addition of letrozole during ovarian stimulation.
2. Materials and Methods
In this randomized clinical trial, 100 women,
aged from 18-40 yr, with normal ovarian response
who were visited the Research and Clinical
Center for Infertility, Yazd, Iran from August to
December of 2018, and planned to undergo
assisted reproduction technology (ART) were
enrolled.
Normal ovarian response was considered as
the antral follicular count >7, and AMH from 1.1- to
3.5 ng/ml.
Our exclusion criteria were:
• A history of endocrine abnormalities
• Intrauterine disorders (intrauterine adhesions,
submucosal fibroma, and uterine polyp)
• Azoospermia of the husband
• Severe endometriosis
The participants were randomly divided into
two equal-sized groups. Sealed envelopes
were the basis for randomization. The case
group received gonadotropin + letrozole +
antagonist. The control group received antagonist
+ gonadotropin.
2.1. Stimulation protocol
From the second day of the cycle, both groups
were subcutaneously administered with 150 units
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of Cinnal-f (CinnaGen, Iran). In addition, from the
second day to the trigger day, the case group
was orally administered with 5 mg of letrozole
(Iran Hormone Company, Iran). In the two groups,
as the size of the dominant follicle reached 12-
13 mm, Cetrotide (Merck, Serono, Germany) 0.25
mg/daily was subcutaneously administered. When
the size of 2-3 follicles amounted to 17 mm,
the last triggering stage was completed with
the intramuscular administration of hCG (Pregnyl,
Merck, Germany). All participants at high risk
of developing OHSS (either those with a past
record of OHSS, those with more than 20 follicles
greater than 10 mm on the day of triggering, or
those with estradiol levels greater than 4,000
pmol/l) were subcutaneously triggered with a
GnRH agonist, specifically 0.2 cc of decapeptyl
(Ferring Co., Germany). Endometrial thickness and
serum E2 levels were measured on the day of hCG
injection. Oocyte retrieval was performed 34-36 hr
after hCG injection, and conventional IVF and/or
intracytoplasmic sperm injection were conducted.
Embryo grading was done by emberyologist,
Grade A embryos had equal size blastomeres
without fragmentation, Grade B embryos had little
difference in blastomeres size, and less than 10%
cytoplasmic fragments. Grade C embryos had
blastomeres with Unequal sized and less than
50% fragments. Embryos were transferred using
a Labotect catheter (Labotect, GmbH, Rosdorf,
Germany) 48-72 hr after oocyte retrieval. The
embryos of participants with a high risk of OHSS
were frozen.
On the oocyte-retrieval day, progesterone
suppositories (Cyclogest®, 400 mg) were
administered vaginally two times per day for
the purpose of luteal-phase support. This was
maintained until ultrasonography demonstrated
fetal heart activity.
Chemical and clinical pregnancy rates were
the major outcomes. The secondary outcomes
consisted of the fertilization rate (percentage
transformation of micro injected oocytes into two
pronuclei), number of mature oocytes (MII), total
dose of gonadotropin, and estradiol level.
Fourteen days after embryo transfer, serum
beta-hCG (β-hCG) was examined. β-hCG > 50
IU/L was regarded as a positive pregnancy
test. In addition, a positive β-hCG 14 days after
embryo transfer was considered as the chemical
pregnancy. Transvaginal ultrasonography, which
was conducted 21 days after positive β-hCG,
was used to diagnose clinical pregnancy as the
identification of fetal heart activities.
2.2. Ethical consideration
This trial was approved by the ethics committee
of the Research and Clinical Center for Infertility,
Shahid Sadoughi University of Medical Sciences,
Yazd, Iran (Code: IR.SSU.RSI.REC.1397.002). In
addition, the study proposal was registered at
the Iranian Registry of Clinical Trials (IRCT) (Code:
IRCT2011050906420N19). The participants were
informed about normal infertility treatments and
IVF processes, after which they provided informed
written consent.
2.3. Statistical analysis
Statistical analysis was carried out using the
Statistical Package for the Social Sciences (SPSS
software), version 20.0, Chicago, Illinois. To
determine the significant differences between
both groups, Student’s t test and Chi-square test
were employed with the significance level set at
p-value < 0.05.
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3. Results
Totally, One hundred participants were included
in this study into two groups (n = 50/each) (Figure
1). As shown in table I, two study groups were
matched in the terms of baseline characteristics.
On the day of hCG administration, estradiol levels
and the total gonadotropin consumption were
significantly higher in the control group (p = 0.045)
(Table II).
The endometrial thickness (was significantly
lower in the case group than the controls (p =
0.002). The number of MII oocytes was higher
(but not significantly) in the case group (p =
0.09), as shown in Table II. Indeed, there were
no significant differences in the fertilization rate
nor the chemical and clinical pregnancy rates
between the two groups (Table III). Embryos were
frozen in two participants of each group because
risk of OHSS.
Table I. Basal characteristics of participants in two study groups (n = 50/each)
Variable Case group Control group p-value
Age (year) (mean ± SD) 29.82 ± 4.11 29.90 ± 3.67 0.91**
Duration of infertility (year) (mean ± SD) 5.88 ± 3.72 6.38 ± 3.16 0.47**
Type of infertility n (%)
Primary 43 (86) 44 (88) 0.77 *
Secondary 7 (14) 6 (12)
AMH (mean ± SD) 2.65 ± 0.69 2.57 ± 0.64 0.29**
Infertility cause n (%)
Male factor 33 (66) 35 (70) 0.53*
Tubal factor 1 (2) 1 (2)
Unexplained 16 (32) 14 (28)
* Chi-square test, ** Student’s t test, AMH: Anti-Mullerian hormone
Table II. Comparison of cycle characteristics in embryo transfer in two study groups (n = 50/each)
Variable Case group Control group p-value
Endometrial thickness (mm) (mean ± SD) 7.89 ± 1.78 9.30 ± 2.53 0.002**
No. of transferred embryos (mean ± SD) 1.78 ± 0.50 1.67 ± 0.68 0.38**
Embryos grade
A (%) 41.7 34.9 0.65*
B (%) 43.8 53.5
C (%) 14.6 11.6
OHSS n (%) 2 (4.0) 2 (4.0) 1.00*
Estradiol level on the day of hCG administration (pg/mL) (mean ± SD) 311.04 ± 229.64 1350.99 ± 833.29 <0.001**
Gonadotropin dose (IU) (mean ± SD) 20.98 ± 5.79 23.72 ± 7.70 0.045**
No. MII oocyte retrieved (mean ± SD) 8.46 ± 4.73 6.96 ± 4.09 0.093**
Freeze embryo transfer cycle n (%) 6 (12) 5 (10) 0.75*
** Students’ t test, * Chi-square test, OHSS: Ovarian hyperstimulation syndrome
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Table III. Comparison of ART outcomes in two study groups (n = 50/each)
Variable Case group Control group p-value
Chemical pregnancy rate, n (%) 12 (24.0) 14 (28.0) 0.65*
Clinical pregnancy rate, n (%) 10 (20.0) 11 (22.0) 0.8*
Fertilization rate, (%) (mean ± SD) 65.60 ± 24.90 62.73 ± 26.90 0.60*
** Student’s t test * Chi-square test
 
Enrollment 
Lost to follow-up (give reasons) (n = 0) 
Ø Discontinued intervention (give reasons) (n = 
0) 
Follow-Up 
Allocated to intervention (n = 50) 
Ø Received allocated intervention (n = 50) 
Ø Did not receive allocated intervention (give 
reasons) (n = 0) 
Allocated to intervention (n = 50) 
Ø Received allocated intervention (n = 50) 
Ø Did not receive allocated intervention (give 
reasons) (n = 0) 
Allocation 
Assessed for eligibility (n = 100) 
Excluded (n = 0) 
Ø Not meeting inclusion criteria (n = 0) 
Ø Declined to participate (n = 0) 
Ø Other reasons (n = 0) 
Lost to follow-up (give reasons) (n = 0) 
Ø Discontinued intervention (give reasons) (n = 0) 
Randomized (n = 100) 
Analyzed (n = 50) 
Ø Excluded from analysis (give reasons) (n = 0) 
Analysis 
Analyzed (n = 50) 
Ø Excluded from analysis (give reasons) (n = 0) 
Figure 1. The COSORT flowchart of the study.
4. Discussion
The hypothesis of the present research
indicated that the adding of letrozole to
gonadotropin in the ovarian stimulation protocol
in normal responder patients could enhance
pregnancy outcomes and decrease gonadotropin
use. Although the results showed no difference
between the two groups in the clinical and
chemical pregnancy rates; the gonadotropin
dose, and estradiol levels decreased in the case
group, significantly. Recently, many studies have
shown letrozole to be advantageous in IVF cycles,
particularly in patients with breast cancer and
undergoing treatment to preserve fertility (9-12).
Moreover, the co-administration of gonadotropin
and letrozole enhances outcomes in normal
responders going through IVF cycles (13-15).
Lazer and co-workers compared pregnancy and
IVF outcomes of poor responder patients to the
treatment with high doses of gonadotropin and
those treated with gonadotropin and letrozole
with minimal doses. Even though no significant
differences were observed in the number of
oocytes retrieved and the eggs fertilized between
the two protocols, a significantly higher rates of
clinical pregnancy and live birth were evident in
the group received minimal-dose of gonadotropin
+ letrozole (16). In an RCT with 94 participants,
Mukherjee and colleagues examined the letrozole
addition to FSH in an antagonist GnRH protocol
for ovarian stimulation cycles and found no
differences in the rate of clinical pregnancy
(36% (15/42) vs. 33% (17/52) p-value 0.82) and
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the mature oocytes’ number (4.6 ± 2.5 vs. 4.9
± 2.3 (p-value 0.55)). Moreover, there were no
OHSS cases in the letrozole group, but seven
cases were present in the control group (17).
In a similar study on normal responders, Haas
J and others reported that co-treatment with
letrozole enhanced the IVF treatment outcomes
by increasing blastocysts and the number of
mature oocytes obtained, without increasing
the risk of OHSS (18). The OHSS risk rate
was the same in the two groups in our study.
Epidemiological research implies that, during
pregnancy, any increase in the estradiol levels
caused by hormone replacement therapy and
oral contraceptive pills is positively correlated
with an increase in the risk of thromboembolic
occurrence. In the course of IVF treatment,
women who develop OHSS with high levels of
estradiol and hemoconcentration are more likely
to be affected by thromboembolic events (19).
Indeed, supraphysiological amounts of estradiol
circulation can reduce the implantation rate as
well as imperfect placentation, thereby causing
pregnancy complications, including intrauterine
growth restriction and small for gestational age,
both of which can be prevented by transferring
frozen embryos when the levels of circulating
estrogen increase (18). The present study
demonstrated that co-treatment with letrozole
reduced estrogen levels, resulting in a decrease
in the possibility of developing thromboembolic
cases and pregnancy complications. Moreover,
the quick endometrial development and the lack
of antiestrogenic impact on the endometrium
could be the positive effects of aromatase
inhibitors in IVF cycles (20). In the RCT on 20
women, Verpoest and co-workers found out that
adding letrozole to FSH in an antagonist GnRH
protocol for controlled ovarian hyperstimulation
did not affect the rate of ongoing pregnancies
(50% vs. 20%) nor the number of the retrieved
oocytes (13.8 ± 9.2 vs. 9.6 ± 7.7). Also, they
reported that, on the day of administering
hCG, the mean of endometrial thickness was
considerably higher in the group administered
with letrozole than that administered without
letrozole (7). Contrastingly, in the present study,
endometrial thickness was significantly lower in
the group administered with letrozole. Moreover,
despite the similar results in the term of cycle
duration in the letrozole group, the overall the
dose of gonadotropin used was significantly
lower, which reduced IVF costs. In addition, the
rate of clinical pregnancy and the number of
transferred embryos were not different between
the cycles in the presence and absence of
letrozole. Indeed, the findings of the present
trial verified the results of previous studies on
normal responder women undergoing IVF for
the diagnosis of severe male factor infertility
using aromatase blockers for controlled ovarian
hyperstimulation (4, 17).
5. Conclusion
Adding letrozole to gonadotropin in women
with normal ovarian response reduces the overall
gonadotropin dose; however, it does not improve
pregnancy outcomes.
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